176 related articles for article (PubMed ID: 33059563)
1. The Place of Pharmacotherapy in Alcohol Use Disorder Management in Family Practice - A Systematic Review.
Morgane GL; Delphine LG; Guillaume K; Yves LJ
Curr Pharm Des; 2021; 27(23):2737-2745. PubMed ID: 33059563
[TBL] [Abstract][Full Text] [Related]
2. Integration of pharmacotherapy for alcohol use disorder treatment in primary care settings: A scoping review.
Hyland CJ; McDowell MJ; Bain PA; Huskamp HA; Busch AB
J Subst Abuse Treat; 2023 Jan; 144():108919. PubMed ID: 36332528
[TBL] [Abstract][Full Text] [Related]
3. Pharmacotherapy for alcohol use disorder among adults with medical disorders in Sweden.
Månsson A; Danielsson AK; Sjöqvist H; Glatz T; Lundin A; Wallhed Finn S
Addict Sci Clin Pract; 2024 May; 19(1):41. PubMed ID: 38764075
[TBL] [Abstract][Full Text] [Related]
4. SAEM GRACE: Anti-craving medications for alcohol use disorder treatment in the emergency department: A systematic review of direct evidence.
Punia K; Scott W; Manuja K; Sabbineni M; Campbell K; Balodis IM; MacKillop J
Acad Emerg Med; 2024 May; 31(5):504-514. PubMed ID: 37735346
[TBL] [Abstract][Full Text] [Related]
5. Strategies to increase implementation of pharmacotherapy for alcohol use disorders: a structured review of care delivery and implementation interventions.
Williams EC; Matson TE; Harris AHS
Addict Sci Clin Pract; 2019 Feb; 14(1):6. PubMed ID: 30744686
[TBL] [Abstract][Full Text] [Related]
6. Baclofen for alcohol use disorder.
Minozzi S; Saulle R; Rösner S
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012557. PubMed ID: 30484285
[TBL] [Abstract][Full Text] [Related]
7. Prescription procedures in medication for relapse prevention after inpatient treatment for alcohol use disorders in Switzerland.
Buri C; Moggi F; Giovanoli A; Strik W
Alcohol Alcohol; 2007; 42(4):333-9. PubMed ID: 17517820
[TBL] [Abstract][Full Text] [Related]
8. Sleep and the Pharmacotherapy of Alcohol Use Disorder: Unfortunate Bedfellows. A Systematic Review With Meta-Analysis.
Panin F; Peana AT
Front Pharmacol; 2019; 10():1164. PubMed ID: 31680952
[No Abstract] [Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
10. Disparities in pharmacotherapy for alcohol use disorder in the context of universal health care: a Swedish register study.
Karriker-Jaffe KJ; Ji J; Sundquist J; Kendler KS; Sundquist K
Addiction; 2017 Aug; 112(8):1386-1394. PubMed ID: 28406579
[TBL] [Abstract][Full Text] [Related]
11. Implementing alcohol use disorder pharmacotherapy in primary care settings: a qualitative analysis of provider-identified barriers and impact on implementation outcomes.
Hagedorn HJ; Wisdom JP; Gerould H; Pinsker E; Brown R; Dawes M; Dieperink E; Myrick DH; Oliva EM; Wagner TH; Harris AHS
Addict Sci Clin Pract; 2019 Jul; 14(1):24. PubMed ID: 31291996
[TBL] [Abstract][Full Text] [Related]
12. Drug therapy for alcohol dependence in primary care in the UK: A Clinical Practice Research Datalink study.
Thompson A; Ashcroft DM; Owens L; van Staa TP; Pirmohamed M
PLoS One; 2017; 12(3):e0173272. PubMed ID: 28319159
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological treatment of alcohol dependence: a review of the evidence.
Garbutt JC; West SL; Carey TS; Lohr KN; Crews FT
JAMA; 1999 Apr; 281(14):1318-25. PubMed ID: 10208148
[TBL] [Abstract][Full Text] [Related]
14. A longitudinal examination of alcohol pharmacotherapy adoption in substance use disorder treatment programs: patterns of sustainability and discontinuation.
Abraham AJ; Knudsen HK; Roman PM
J Stud Alcohol Drugs; 2011 Jul; 72(4):669-77. PubMed ID: 21683049
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological Treatment of Alcohol use Disorder in Patients with Psychotic Disorders: A Systematic Review.
Rosenstand NJ; Nielsen AS; Skøt L; Anhøj S; Nielsen DG; Højlund M; Mellentin AI
Curr Neuropharmacol; 2024; 22(6):1129-1143. PubMed ID: 36582063
[TBL] [Abstract][Full Text] [Related]
16. Barriers to and facilitators of pharmacotherapy for alcohol use disorder in VA residential treatment programs.
Finlay AK; Ellerbe LS; Wong JJ; Timko C; Rubinsky AD; Gupta S; Bowe TR; Burden JL; Harris AHS
J Subst Abuse Treat; 2017 Jun; 77():38-43. PubMed ID: 28476269
[TBL] [Abstract][Full Text] [Related]
17. Combined Pharmacotherapy and Cognitive Behavioral Therapy for Adults With Alcohol or Substance Use Disorders: A Systematic Review and Meta-analysis.
Ray LA; Meredith LR; Kiluk BD; Walthers J; Carroll KM; Magill M
JAMA Netw Open; 2020 Jun; 3(6):e208279. PubMed ID: 32558914
[TBL] [Abstract][Full Text] [Related]
18. Overview of Alcohol Use Disorder.
Kranzler HR
Am J Psychiatry; 2023 Aug; 180(8):565-572. PubMed ID: 37525595
[TBL] [Abstract][Full Text] [Related]
19. Pharmacotherapy for alcohol use disorders - Unequal provision across sociodemographic factors and co-morbid conditions. A cohort study of the total population in Sweden.
Wallhed Finn S; Lundin A; Sjöqvist H; Danielsson AK
Drug Alcohol Depend; 2021 Oct; 227():108964. PubMed ID: 34518028
[TBL] [Abstract][Full Text] [Related]
20. Evidence based models of care for the treatment of alcohol use disorder in primary health care settings: a systematic review.
Rombouts SA; Conigrave JH; Saitz R; Louie E; Haber P; Morley KC
BMC Fam Pract; 2020 Dec; 21(1):260. PubMed ID: 33278891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
